Veeva Systems (VEEV)
Software empresarial / Nube / Ciencias de la vida
Leading cloud software provider specific to the life sciences industry, with high regulatory switching costs, expanding margins, and net cash of more than US$7,000M with no debt; the moat shows signs of erosion in its CRM segment against Salesforce, which caps the multiple despite the quality of the business.
- Price
- $244.83
- Intrinsic value (5y, base)
- $317
- Total annual return (5y)
- 5.3%
- Status (nominal)
- Fairly valued
- Margin of safety
- +4%
The essentials
- Real regulatory moat (switching costs, 12+ month sales cycles) but with declared erosion in its largest segment, Commercial Solutions, from the migration to Salesforce
- Net cash of more than US$7,000M with no debt, funding growth and a new US$2,000M buyback program without leveraging the balance sheet
- Expanding margins: GAAP operating margin went from 18.2% (FY24) to 28.7% (FY26) on operating leverage
- High stock-based compensation (14.5% of revenue, 28.8% of cash flow): the NOPAT-based valuation expenses it by construction
- Company guidance for fiscal 2027 of +13.9% revenue growth, an orderly deceleration from 16.3% in the latest fiscal year
Intrinsic value — two valuation methods
The methods disagree: one places the value today above the price ($245) and the other below.
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $245 trades ~3.8% below its value discounted to today (~$254); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — En valor: the target price ($317) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$158.
Thesis
The business
High-margin, minimal-capital cloud software, with real regulatory switching costs and a customer base that concentrates most of the world's large pharmaceutical companies. Quality is high but uneven: R&D and Quality Solutions sustains the moat better than Commercial Solutions, where the migration to Vault CRM opens a window for customer defection to Salesforce.
The valuation
Valued on EV/NOPAT — operating income already expenses stock-based compensation (14.5% of revenue), avoiding the trap of adding it back the way reported FCF and adjusted EBITDA do. With an exit multiple of 24x on year-5 NOPAT (enterprise-software band 20-30x, at the midpoint given the declared erosion of the moat), the 5-year value is $317, versus the current price of $245: a CAGR of +5%.
The margin of safety
It trades close to intrinsic value, far from the required margin of safety. The verdict is Fairly valued. Net cash of more than US$7,000M with no debt provides additional cushion not captured in the multiple: it funds growth and the new buyback program without leveraging the balance sheet.
What to watch
The test that would refute the thesis is the speed of customer migration from Veeva CRM to Salesforce during the transition to Vault CRM (supported through 2029): if the defection accelerates before Vault CRM gains sufficient traction (150 live customers as of April 2026), Veeva's largest segment loses market share at its moment of greatest vulnerability.
Educational / informational. Does not constitute investment advice.